Oncology News

The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma.

Living-donor liver transplantation may be a viable option for patients with unresectable, liver-confined colorectal cancer liver metastases, according to a study published in JAMA Surgery.

Nonalcoholic fatty liver disease correlated with lower hepatocellular carcinoma surveillance receipt, early-stage detection and poorer survival compared with other HCC etiologies, according to research.

The AGA published 11 recommendations for systemic therapy in patients with hepatocellular carcinoma, which were featured in Gastroenterology.

The FDA granted orphan drug designation to two investigational T-cell immunotherapies for the treatment of advanced hepatocellular carcinoma.

Molecules in saliva may be highly sensitive and specific noninvasive biomarkers of hepatocellular carcinoma, according to a study published in PeerJ.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.